These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6430068)

  • 1. Comparison of continuous and intermittent Factor VIII concentrate therapy in hemophilia A.
    Hathaway WE; Christian MJ; Clarke SL; Hasiba U
    Am J Hematol; 1984 Jul; 17(1):85-8. PubMed ID: 6430068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of continuous infusion of factor concentrates in the treatment of hemophilia.
    Bona RD; Weinstein RA; Weisman SJ; Bartolomeo A; Rickles FR
    Am J Hematol; 1989 Sep; 32(1):8-13. PubMed ID: 2502914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII procoagulant antigen recovery is a dose-related response to Factor VIII concentrate infusions.
    Taylor L; Ekert H; Dean F
    Haemostasis; 1984; 14(4):296-301. PubMed ID: 6437942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR; Doughty HI; Savidge GF
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion.
    Morfini M; Messori A; Longo G
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S11-4. PubMed ID: 8735791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
    Goldsmith JC
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Surgery and the acquired inhibitor of factor VIII coagulant].
    Vivin P; Helmer J; Kipper R; Thome M; Briquel ME
    Ann Fr Anesth Reanim; 1986; 5(3):322-5. PubMed ID: 3096169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous and intermittent infusion of coagulation factor concentrates in patients undergoing surgery: a single centre Australian experience.
    Campbell PJ; Rickard KA
    Aust N Z J Med; 1998 Aug; 28(4):440-5. PubMed ID: 9777111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of monoclonal antibody-purified factor VIII.
    Weinstein RE; Bona RD; Rickles FR
    Am J Hematol; 1991 Mar; 36(3):211-2. PubMed ID: 1899966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful preoperative apheresis of factor VIII antibody using factor VIII concentrate as a replacement fluid.
    Apter B; McCarthy V; Shapiro SS; Ballas SK
    J Clin Apher; 1986; 3(2):140. PubMed ID: 3084459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preliminary experience with achieving immune tolerance in patients with hemophilia A and circulating factor VIII inhibitor].
    Scharf R; Kucharski W; Lopaciuk S; Celińska W; Dmytrow A; Domański K; Gonet S; Miastkowski Z; Nowakowska I; Przybylski A
    Acta Haematol Pol; 1991; 22(1):92-9. PubMed ID: 1823972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Substitutive treatment of hemopjolia A using a new factor VIII concentrate].
    Allain JP; Steinbuch M; Meunier L; Muller JY; Soulier JP
    Nouv Presse Med; 1976 Apr; 5(16):1047-50. PubMed ID: 1272773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma fractions for the treatment of hemophilia. 1. On the preparation and use of fraction I-O.
    Blombäck M; Blombäck B
    Thromb Diath Haemorrh Suppl; 1969; 35():21-5. PubMed ID: 5317539
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions.
    Schimpf K; Mannucci PM; Kreutz W; Brackmann HH; Auerswald G; Ciavarella N; Mösseler J; DeRosa V; Kraus B; Brueckmann C
    N Engl J Med; 1987 Apr; 316(15):918-22. PubMed ID: 3102963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
    Smith KJ; Lusher JM; Cohen AR; Salzman P
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose requirement for replacement therapy in hemophilia A.
    Allain JP
    Thromb Haemost; 1979 Oct; 42(3):825-31. PubMed ID: 505399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A.
    Martinowitz U; Schulman S; Gitel S; Horozowski H; Heim M; Varon D
    Br J Haematol; 1992 Dec; 82(4):729-34. PubMed ID: 1482660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
    Guérois C; Laurian Y; Rothschild C; Parquet-Gernez A; Duclos AM; Négrier C; Vicariot M; Fimbel B; Fressinaud E; Fiks-Sigaud M
    Thromb Haemost; 1995 Feb; 73(2):215-8. PubMed ID: 7792732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.